Oren Gilad

Oren Gilad appears in our data through filings on Aprea Therapeutics, Inc. shares, published by SEC (Form 4). The record holds 13 filings, for trades running from 28 July 2022 to 12 March 2026.

No open-market sale appears; the market trades are 7 purchases worth €45k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 5 share grants. So far in 2026, the count stands at 1 purchase and no sales.

Half of the purchases are above €2,374 and half below. On 6 out of 7 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. For 7 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 57% of cases, with a median move of +3.4%. This is a record of the past, not a forecast.

The newest entry dates from 16 March 2026: a share grant, in Aprea Therapeutics, Inc. The latest purchase dates back some time: it was published 266 days ago, on 2 February 2026. Typically, a trade is published a median of 4 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.